Medroxyprogesterone acetate
- Generic Name
- Medroxyprogesterone acetate
- Brand Names
- Depo-provera, Depo-subq Provera, Premphase 28 Day, Prempro 0.625/2.5 28 Day, Provera
- Drug Type
- Small Molecule
- Chemical Formula
- C24H34O4
- CAS Number
- 71-58-9
- Unique Ingredient Identifier
- C2QI4IOI2G
- Background
Medroxyprogesterone acetate (MPA) is a progesterone derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prevent pregnancy, manage pain in endometriosi...
- Indication
Medroxyprogesterone acetate (MPA) oral tablets are indicated to treat secondary amenorrhea, reduce the incidence of endometrial hyperplasia in postmenopausal women, and to treat abnormal uterine bleeding due to hormonal imbalance, not organic pathology. Oral tablets containing MPA and conjugated estrogens are indicated to prevent postmenopausal osteoporosis ...
- Associated Conditions
- Abnormal Uterine Bleeding, Amenorrhea, Endometrial Hyperplasia, Endometriosis related pain, Metastatic Renal Cell Carcinoma ( mRCC), Osteoporosis, Pain, Postmenopausal Osteoporosis, Pregnancy, Vasomotor Symptoms Associated With Menopause, Vulvo Vaginal Atrophy, Metastatic Endometrial carcinoma
- Associated Therapies
- Contraception, Estrogen Replacement Therapy, Hormonal Contraception therapy
PK of Depo SubQ Injected in the Upper Arm
- First Posted Date
- 2010-06-14
- Last Posted Date
- 2013-08-19
- Lead Sponsor
- FHI 360
- Target Recruit Count
- 26
- Registration Number
- NCT01143207
- Locations
- 🇺🇸
Clinical Research Center, Dept. of Obstetrics & Gynegology, Eastern Virginia Medical School, Norfolk, Virginia, United States
Study of Self or Clinic Administration of DepoProvera
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2019-05-07
- Lead Sponsor
- Carolyn L. Westhoff
- Target Recruit Count
- 132
- Registration Number
- NCT01019369
- Locations
- 🇺🇸
Columbia University/New York Presbyterian Hospital, New York, New York, United States
Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2009-11-11
- Last Posted Date
- 2015-07-30
- Lead Sponsor
- Takeda
- Target Recruit Count
- 311
- Registration Number
- NCT01011751
- Locations
- 🇫🇷
Professor Jacques IRANI, Poitiers, France
Medroxyprogesterone Acetate Injection 150 mg/1 mL in Postmenopausal Women
- First Posted Date
- 2009-01-27
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 124
- Registration Number
- NCT00830414
- Locations
- 🇩🇪
AAI Deutschland GmbH & Co. KG, Neu-Ulm, Germany
Study in Women With Idiopathic Menorrhagia to Determine the Reduction in Menstrual Blood Loss (MBL) After Treatment With the Levonorgestrel-releasing Intrauterine System (IUS)
- Conditions
- Interventions
- First Posted Date
- 2006-08-04
- Last Posted Date
- 2013-12-09
- Lead Sponsor
- Bayer
- Target Recruit Count
- 165
- Registration Number
- NCT00360490
Treatment of Non-Gestational Acute Uterine Bleeding: A Randomized Trial
- Conditions
- First Posted Date
- 2006-07-10
- Last Posted Date
- 2015-03-11
- Lead Sponsor
- Kaiser Permanente
- Target Recruit Count
- 240
- Registration Number
- NCT00350480
- Locations
- 🇺🇸
Kaiser Permanente Sunset, Los Angeles, California, United States
Study of Hot Flashes and Night Sweats in Postmenopausal Women Receiving Combination Raloxifene and Oral Estrogen
- Conditions
- First Posted Date
- 2006-06-01
- Last Posted Date
- 2007-05-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 150
- Registration Number
- NCT00332553
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877- CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States
Cytokines in Patients With Metastatic Renal Cell Carcinoma of Intermediate Prognosis
- Conditions
- First Posted Date
- 2006-02-14
- Last Posted Date
- 2006-02-16
- Lead Sponsor
- Centre Leon Berard
- Target Recruit Count
- 456
- Registration Number
- NCT00291369
- Locations
- 🇫🇷
Centre Leon Berard, Lyon, France
Somatropin Treatment to Final Height in Turner Syndrome
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-01-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 154
- Registration Number
- NCT00191113
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 am - 5 pm Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sherbrooke, Quebec, Canada
Estrogen, HDL, and Coronary Heart Disease in Women
- First Posted Date
- 2004-06-04
- Last Posted Date
- 2016-04-21
- Lead Sponsor
- Tufts University
- Target Recruit Count
- 309
- Registration Number
- NCT00083824
- Locations
- 🇺🇸
HNRCA at Tufts University, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.